Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer

Gynecologic Oncology

Volumn 96, Issue 2, 2005, Pages 323-329

  Watanabe, Yoh ^a   Nakai, Hidekatsu ^a   Ueda, Haruhiko ^a   Hoshiai, Hiroshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CBDCA; Paclitaxel; Recurrent ovarian cancer; Weekly administration

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 12344265603     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.09.029     Document Type: Article

References (31)

1. M.K. Parmar, J.A. Ledermann, N. Colombo, A. du Bois, J.F. Delaloye, and G.B. Kristensen Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 2003 2094 2095
2. T. Gilewski, and L. Norton Cytokinetics and breast cancer chemotherapy J.R. Harris M.E. Lippman M. Morrow Diseases of the Breast 1996 Lippincott-Raven Philadelphia (PA) 751 768
3. A.D. Seidman, C.A. Hudis, and J. McCaffrey Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer Semin. Oncol. 17 1997 72 76
4. N.R. Abu-Rustam, C. Aghajanian, R.R. Barakat, D. Fennelly, F. Shapiro, and D. Spriggs Salvage weekly paclitaxel in recurrent ovarian cancer Semin. Oncol. 24 1997 62 67
5. M. Markman, J. Hall, D. Spitz, S. Weiner, L. Carson, and L. Van Le Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer J. Clin. Oncol. 20 2002 2365 2369
6. L.J. Havrilsky, A.A. Alvarez, and R.A. Sayer Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer Gynecol. Oncol. 88 2003 51 57
7. C.H. Wu, C.H. Yang, J.N. Lee, and E.M. Tsai Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects Int. J. Gynecol. Cancer 11 2001 295 299
8. G. Bolis, G. Scarfone, L. Luchini, C. Ferraris, F. Zanaboni, and M. Presti Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen Eur. J. Cancer 30A 1994 1739 1741
9. N. Colombo, M. Pittelli, G. Parma, M. Marzola, W. Torri, and C. Mangoni Cisplatin dose intensity in ovarian cancer: a randomized study of conventional dose versus dose-intense cisplatin monochomotherapy Proc. Am. Soc. Clin. Oncol. 12 1993 806a
10. G. Cocconi, M. Bella, F. Lottici, F. Leonardi, G. Ceci, and R. Passalacqua Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma Am. J. Clin. Oncol. 22 1999 559 567
11. C.P. Belani, J. Barstis, M.C. Perry, R.V. La Rocca, S.R. Nattam, and D. Rinaldi Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation J. Clin. Oncol. 21 2003 2933 2939
12. Y. Watanabe, H. Nakajima, K. Nozaki, H. Hoshiai, and K. Noda The effect of granisetron on in vitro metabolism of paclitaxel and docetaxel Cancer J. 9 2003 67 70
13. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winker Reporting results of cancer treatment Cancer 47 1981 207 214
14. G.J. Rustin, A.E. Nelstop, P. McClean, M.F. Brady, W.P. Mcguire, and W.J. Hoskins Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 J. Clin. Oncol. 14 1996 1545 1551
15. G.J. Rustin, A.E. Nelstop, S.M. Bentzen, M.J. Piccart, and K. Bertelson Use of tumour markers in monitoring the course of ovarian cancer Ann. Oncol. 10 1999 21 27
16. A. du Bois, H.J. Luck, K. Buser, H.G. Meerpohl, C. Sessa, and U. Klaassen Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum Eur. J. Cancer 33 1997 379 384
17. M. Nardi, A. Aloe, S. DeMarco, F. Cognetti, A. Iacovelli, and G. Atlante Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study Am. J. Clin. Oncol. 20 1997 230 232
18. A. du Bois, H.J. Luck, W. Meier, H.P. Adams, V. Mobius, and S. Costa A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J. Natl. Cancer Inst. 95 2003 1320 1330
19. R.F. Ozols Management of advanced ovarian cancer consensus summary Semin. Oncol. 3 2000 47 49
20. D. Fennelly, C. Aghajanion, F. Shopiro, C. O'Flaherty, M. McKenzie, and W. O'Connor Phase I and pharmacologic study of paclitaxel administrated weekly in patients with relapsed ovarian cancer J. Clin. Oncol. 15 1997 187 192
21. P. Rosenberg, H. Anderson, K. Boman, M. Ridderheim, B. Sorbe, and U. Puistola Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum Acta Oncol. 41 2002 418 424
22. J. Sehouli, D. Stengel, D. Elling, O. Ortmann, J. Blohmer, and H. Riess First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study Gynecol. Oncol. 85 2002 321 326
23. M.J. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni, and E. Simonsen Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J. Natl. Cancer Inst. 92 2000 699 708
24. ICON Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomized trial Lancet 360 2002 505 515
25. M.A. Bookman, B.E. Greer, and R.F. Ozols Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG 0182-ICON5 Int. J. Gynecol. Cancer 13 2003 735 740
26. W.P. Mcguire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Engl. J. Med. 334 1996 1 6
27. N.M. Lopes, E.G. Adams, T.W. Pitts, and B.K. Bhuyan Cell kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines Cancer Chemother. Pharmacol. 32 1993 235 242
28. M.A. Jordan, K. Wendell, S. Gardiner, W.B. Derry, H. Copp, and L. Wilson Mitotic block induced in Hela cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death Cancer Res. 56 1996 816 825
29. D.S. Dizon, M.L. Hensley, E.A. Poynor, P. Sabbatini, C. Aghajanian, and A. Hummer Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer J. Clin. Oncol. 20 2002 1238 1247
30. G.H. Eltabbakh, Z. Yildirim, and R. Adamowicz Paclitaxel and carboplatin as second-line therapy in women with platinum-sensitive ovarian carcinoma treated with platinum and paclitaxel as first-line therapy Am. J. Clin. Oncol. 27 2004 46 50
31. P.G. Rose, N. Fusco, L. Fluellen, and M. Rodriguez Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma J. Clin. Oncol. 16 1998 1494 1497